GlaxoSmithKline plc operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares GlaxoSmithKline plc with three other
pharmaceutical manufacturers in Europe:
sales of 51.94 billion Swiss Francs [US$52.62 billion]
of which 66%
was Innovative Medicines),
(35.68 billion Euro [US$39.55 billion]
of which 69%
was Pharmaceuticals), and
based in Germany
(39.59 billion Euro [US$43.89 billion]
of which 42%
was Pharmaceuticals & Biological Products).
During the year ended December of 2018, sales at
GlaxoSmithKline plc were £30.82 billion (US$40.03 billion).
increase of 2.1%
versus 2017, when the company's sales were £30.19 billion.
This was the fourth straight year of sales growth at GlaxoSmithKline plc.
Sales of Vaccines saw an increase
that was more than double the company's growth rate: sales were up
14.2% in 2018, from
£5.16 billion to £5.89 billion.
Not all segments of GlaxoSmithKline plc experienced an increase in sales in 2018:
sales of Consumer Healthcare fell 1.2% to £7.66 billion.
GlaxoSmithKline plc also experienced decreases in sales in
Pharmaceuticals (down 0.0% to £17.27 billion)